FOR HEALTHCARE PROFESSIONALS ONLY. Developed by Janssen Pharmaceuticals, Inc., the REMICADE® (infliximab) IBD Resource Center App is designed specifically to give healthcare professionals the latest clinical information about REMICADE® and the treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). It features a safety checklist for using REMICADE®, IBD news, and gastroenterologist videos. The REMICADE® IBD Resource Center App also features access to the full US Prescribing Information (PI) and Dosing Guidelines. An educational module featuring anatomical models is included to use during patient consultations to help explain to patients their condition(s) as well as educate them about Crohn’s and UC, how REMICADE® works, and why it may be prescribed.
Please report all product complaints, including side effects and/or adverse events to the Janssen Scientific Affairs, LLC Medical Information Center at 1-800-JANSSEN (1-800-526-7736). This App is not a medical device. The App and the information generated from it should not be used as a basis for any diagnosis, monitoring, management, or treatment. The App is intended for use as an educational tool. Any calculations should be verified using traditional scoring techniques and clinical judgment.
Data rates from your carrier may apply. Janssen does not charge for use of this application.
© Janssen Biotech, Inc. 2015. All Rights Reserved. This application is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. Please read our Privacy Policy and Terms of Use.